Commentary on “Weekly Low‐Dose Versus Three‐Weekly High‐Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non‐Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta‐Analysis of Aggregate Data”

Assessing a recent retrospective analysis, conclusions differ on whether a weekly regimen could be adopted as a reasonable standard of care option. This commentary questions how study results are interpreted, what considerations are most important for patient care, and where efforts should be focused for the next generation of trials.